Results 11 to 20 of about 48,162 (201)

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. [PDF]

PLoS ONE, 2011
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design. The extent of cross-clade conservation of HIV oligomannose glycans is therefore a critical consideration for the development of HIV prophylaxes.
Camille Bonomelli, Katie J Doores, D Cameron Dunlop, Victoria Thaney, Raymond A Dwek, Dennis R Burton, Max Crispin, Christopher N Scanlan   +7 more
doaj   +1 more source

Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. [PDF]

PLoS ONE, 2012
HIV-1 envelope protein gp120 has been extensively studied for neurotoxic effects that have been attributed to the increased expression of various proinflammatory cytokines in the CNS.
Ankit Shah, Peter S Silverstein, Santosh Kumar, Dhirendra P Singh, Anil Kumar   +4 more
doaj   +1 more source

Blood–brain barrier abnormalities caused by exposure to HIV-1 gp120 — Protection by gene delivery of antioxidant enzymes

Neurobiology of Disease, 2010
HIV-1 effects on the blood–brain barrier (BBB) structure and function are still poorly understood in animal models based on direct administration of recombinant HIV proteins.
Jean-Pierre Louboutin, Beverly A.S. Reyes, Lokesh Agrawal, Christina R. Maxwell, Elisabeth J. Van Bockstaele, David S. Strayer   +5 more
doaj   +1 more source

Effect of naringin on gp120-induced injury mediated by P2X7 receptors in rat primary cultured microglia. [PDF]

PLoS ONE, 2017
Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein 120 has been shown to activate microglia, causing release of inflammatory and toxic factors.
Qiang Chen, Hui Wu, Jia Tao, Chenglong Liu, Zeyu Deng, Yang Liu, Guoqiao Chen, Baoyun Liu, Changshui Xu   +8 more
doaj   +1 more source

Long Non-coding RNA Uc.48+ Small Interfering RNA Alleviates Neuroinflammatory Hyperalgesia in Gp120-Treated Rats via the P2Y12 Receptor

Frontiers in Neuroscience, 2021
Human immunodeficiency virus envelope glycoprotein 120 (gp120) leads to hyperalgesia. Long non-coding RNAs are characterized by the lack of a protein-coding sequence and may contribute to the development and maintenance of inflammatory and ...
Lichao Peng, Bing Wu, Bing Wu, Liran Shi, Liran Shi, Lifang Zou, Lifang Zou, Lin Li, Lin Li, Runan Yang, Runan Yang, Xiumei Xu, Xiumei Xu, Guilin Li, Guilin Li, Shuangmei Liu, Shuangmei Liu, Chunping Zhang, Chunping Zhang, Shangdong Liang, Shangdong Liang   +20 more
doaj   +1 more source

Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding [PDF]

, 2016
The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120SU plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target.
Bess, JW, Binet, D, Bouché, L, Canis, K, Chertova, E, Dell, A, Desrosiers, RC, Haslam, SM, Keele, BF, Lifson, JD, Morris, HR, North, SJ, O'Connor, MJ, Pang, PC, Panico, M, Rahman, D   +15 more
core   +1 more source

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

PLoS Pathogens, 2007
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is a vaccine immunogen that can signal via several cell surface receptors.
Meimei Shan, Per Johan Klasse, Kaustuv Banerjee, Antu K Dey, Sai Prasad N Iyer, Robert Dionisio, Dustin Charles, Lila Campbell-Gardener, William C Olson, Rogier W Sanders, John P Moore   +10 more
doaj   +1 more source

Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120 [PDF]

, 2001
BACKGROUND: Cellulose acetate phthalate (CAP), a pharmaceutical excipient used for enteric film coating of capsules and tablets, was shown to inhibit infection by the human immunodeficiency virus type 1 (HIV-1) and several herpesviruses. CAP formulations
A Boyum, A Robert Neurath, A Trkola, A Trkola, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, AR Neurath, Asim K Debnath, CD Rizzuto, CK Lapham, CM Javan, DR Burton, DR Littman, EA Berger, F Cocchi, G Alkhatib, H Choe, H Deng, J Bilello, JA Este, JC Lee, K Javaherian, KH Manson, L Wu, L Xiao, M Baba, M Baba, M Moulard, M Thali, MA Skinner, MC Peitsch, Nathan Strick, P Greenhead, PD Kwong, RA Anderson, RA Maguire, RF Speck, RJ Shattock, S Harada, S Laal, S Matsushita, S Rusconi, S Shaunak, T Dragic, T Gyotoku, T Kawamura, T Muster, TN Hart, WR Melander, Y Feng, YI Rumyantseva, Yun-Yao Li   +55 more
core   +3 more sources

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. [PDF]

PLoS ONE, 2015
In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein with the capacity to trigger broad B and T-cell responses.
Aneesh Vijayan, Juan García-Arriaza, Suresh C Raman, José Javier Conesa, Francisco Javier Chichón, César Santiago, Carlos Óscar S Sorzano, José L Carrascosa, Mariano Esteban   +8 more
doaj   +1 more source

Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy [PDF]

, 2007
The successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. Here we demonstrate cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer. The
Haitang Li, Jiehua Zhou, John Rossi, John Zaia, Shirley Li   +4 more
core   +2 more sources